About this source
- Kind
- Research
- Design
- Meta-analysis, RCT
- Population
- Human, HIV-associated lipodystrophy, pooled across 5 RCTs
- Sample size
- 5 RCTs pooled
- Primary or secondary
- secondary
- Peer review
- peer reviewed
- Retraction status
- None known
- Date checked
- 14 August 2026
Limitations
Results apply to people with HIV-associated lipodystrophy only.
Cited in
2026 meta-analysis, five trials
Tesamorelin · Research finding
StrongPooled trial adverse-event reporting
Tesamorelin · Safety finding
Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.